Onkologie. 2024:18(3):180-183 | DOI: 10.36290/xon.2024.033

Stereotactic body radiation therapy for prostate cancer

Pavel Krupa
Klinika radiační onkologie, LF MU a MOÚ, Brno

Stereotactic radiotherapy of prostate cancer is a new technique for the treatment of this disease. It is used as an alternative to commonly used fractionation schemes in curative indications when irradiating the entire prostate and part of the seminal vesicles and in palliative cases when irradiating distant pathways. It is particularly useful in the treatment of oligometastatic disease.

Keywords: stereotactic radiotherapy, prostate carcinoma, oligometastatic dissease, SBRT, SABR.

Accepted: June 18, 2024; Published: June 24, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krupa P. Stereotactic body radiation therapy for prostate cancer. Onkologie. 2024;18(3):180-183. doi: 10.36290/xon.2024.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. van As N, Tree A, Patel J, et al. 5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2023;117(4):e2-e3. doi: 10.1016/j.ijrobp.2023.08.027. Go to original source...
    2. Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet. 2019;394. doi: 10.1016/S0140-6736(19)31131-6. Go to original source... Go to PubMed...
    3. Kishan AU, Dang A, Katz AJ, et al. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019;2(2):e188006-e188006. doi: 10.1001/jamanetworkopen.2018.8006. Go to original source... Go to PubMed...
    4. Greco C, Pares O, Pimentel N, et al. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(5):700-708. doi: 10.1001/JAMAONCOL.2021.0039. Go to original source... Go to PubMed...
    5. Jackson WC, Silva J, Hartman HE, et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology*Biology*Physics. 2019;104(4):778-789. doi: https://doi.org/10.1016/j.ijrobp.2019.03.051. Go to original source... Go to PubMed...
    6. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899-905. doi: https://doi.org/10.1016/S0090-4295(00)00858-X. Go to original source... Go to PubMed...
    7. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiotherapy and Oncology. 2013;109(2):217-221. doi: 10.1016/j.radonc.2013.08.030. Go to original source... Go to PubMed...
    8. Marvaso G, Volpe S, Pepa M, et al. Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol Open Sci. 2021;27:19-28. doi: https://doi.org/10.1016/j.euros.2021.02.008. Go to original source... Go to PubMed...
    9. Battaglia A, De Meerleer G, Tosco L, et al. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. Eur Urol Oncol. 2019;2(2):174-188. doi: https://doi.org/10.1016/j.euo.2018.09.005. Go to original source... Go to PubMed...
    10. Kneebone A, Hruby G, Ainsworth H, et al. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2018;1(6):531-537. doi: https://doi.org/10.1016/j.euo.2018.04.017. Go to original source... Go to PubMed...
    11. Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018;74(4):455-462. doi: https://doi.org/10.1016/j.eururo.2018.06.004. Go to original source... Go to PubMed...
    12. Bowden P, See AW, Frydenberg M, et al. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Int J Cancer. 2020;146(1):161-168. doi: 10.1002/IJC.32509. Go to original source... Go to PubMed...
    13. Ost P, Reynders D, Decaestecker K, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Go to original source... Go to PubMed...
    14. Zilli T, Achard V, Dal Pra A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. Radiotherapy and Oncology. 2022;176:199-207. doi: https://doi.org/10.1016/j.radonc.2022.10.005. Go to original source... Go to PubMed...
    15. Wolf F, Sedlmayer F, Aebersold D, et al. Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer. Strahlentherapie Und Onkologie. 2021;197(2):89. doi: 10.1007/S00066-020-01723-8. Go to original source... Go to PubMed...
    16. Gomez-Iturriaga A, Büchser D, Lopez-Campos F, et al. Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities. Clin Transl Radiat Oncol. 2024;45:100733. doi: https://doi.org/10.1016/j.ctro.2024.100733. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.